A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Findings indicate that dapagliflozin and calorie restriction together improve weight loss and metabolic health, increasing ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

Russell Wooten of Hendersonville, North Carolina, has spent much of his life struggling with obesity, often carrying 260 pounds on his 6-foot-3 frame. He repeatedly starved himself to lose weight, ...

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

Novo Nordisk's (NVO) stock was up more than 12% in pre-market trading Friday on news the company's latest weight loss product ...

Oprah Winfrey has admitted to using an unnamed weight-loss drug to manage her weight and says doing so has changed her ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

Professor Tim Spector has issued an urgent warning to people who may wish to take Ozempic "without a medical need". Ozempic ...

People can reverse their type 2 diabetes through a combination of calorie cutting and medication, a small clinical tri ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...